ZOSTAVAX® Patient Handout Generic Name: Zoster Vaccine Live
Pharmacy & Pharmacology International Journal · 2015
DOI: 10.15406/ppij.2015.02.00012 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacy & Pharmacology International Journal, 2015. Verfasst von Anthony LaMendola.
Abstract (Originalsprache)
Anybody who has had the varicella zoster virus (chickenpox) is at risk for acquiring shingles. The varicella zoster virus can remaining your nervous system for many years and remains dormant. Research has been done and although it’s not fully understood, the virus may become active again and give you shingles. The elderly and/or a lowered immune system may increase your probabilities of getting shingles. Shingles is a rash or blisters that emergeon the skin, typically on one side of the body. The rash may be painful and long-lasting for some patients. Shingles rashes typically last for up to 30 days and, for most people, the pain from the rash reduces as it heals.
Zitieren
APA
LaMendola, A. (2015). ZOSTAVAX® Patient Handout Generic Name: Zoster Vaccine Live. Pharmacy & Pharmacology International Journal. https://doi.org/10.15406/ppij.2015.02.00012
Vancouver
LaMendola A. ZOSTAVAX® Patient Handout Generic Name: Zoster Vaccine Live. Pharmacy & Pharmacology International Journal. 2015. doi:10.15406/ppij.2015.02.00012
BibTeX
@article{LaMendola2015,
author = {LaMendola, Anthony},
title = {ZOSTAVAX® Patient Handout Generic Name: Zoster Vaccine Live},
journal = {Pharmacy & Pharmacology International Journal},
year = {2015},
doi = {10.15406/ppij.2015.02.00012}
}
EUVIMED